The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

2025/09/26 19:16

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

BullZilla Presale Leads the Best Crypto Presales Now While Toncoin and Bitcoin Cash See Price Drops

BullZilla Presale Leads the Best Crypto Presales Now While Toncoin and Bitcoin Cash See Price Drops

The post BullZilla Presale Leads the Best Crypto Presales Now While Toncoin and Bitcoin Cash See Price Drops appeared on BitcoinEthereumNews.com. Disclaimer: This content is a sponsored article. Bitcoinsistemi.com is not responsible for any damages or negativities that may arise from the above information or any product or service mentioned in the article. Bitcoinsistemi.com advises readers to do individual research about the company mentioned in the article and reminds them that all responsibility belongs to the individual. Are today’s market pullbacks actually an opportunity? With Toncoin sliding, Bitcoin Cash dipping, and the BullZilla Presale roaring past $430k, investors are asking if these could be the Best Crypto Presales Now. Early presales have historically delivered outsized gains when timed correctly. Crypto traders are increasingly eyeing presale tokens that show strong community growth and unique utility. Among the standouts, Bull Zilla is catching attention as the best meme coin 2025, offering $BZIL staking rewards and a presale ROI already exceeding 8,800%. Below, we break down the latest news and data on Toncoin, BullZilla, and Bitcoin Cash, giving you everything you need to evaluate the Best Crypto Presales Now. Toncoin Shows a Modest Pullback Amid Broader Market Uncertainty Toncoin (TON) trades at $3.15, reflecting a -1.30% 24-hour dip and $148M in trading volume. While the token faces short-term selling pressure, Toncoin continues to build its ecosystem around fast, scalable messaging-based blockchain technology. Analysts note that dips like today’s often precede accumulation phases, especially if network activity remains robust. Toncoin’s developers are rolling out updates to improve cross-chain compatibility, which could set up a rebound later this year. For investors hunting the Best Crypto Presales Now, Toncoin’s current price weakness might be attractive—but it lacks the explosive upside of newer presale plays like BullZilla. BullZilla Presale Breaks $430k: The Best Meme Coin 2025? The BullZilla Presale continues to capture headlines. Current Stage: 3rd (404: Whale Signal Detected), Phase: 1st, with a price of $0.00005908. Over…
Share
BitcoinEthereumNews2025/09/18 11:00
Share
Brazil holds key interest rate at 15%

Brazil holds key interest rate at 15%

The post Brazil holds key interest rate at 15% appeared on BitcoinEthereumNews.com. Holding borrowing costs at the highest level in nearly two decades, Brazil’s central bank left its benchmark Selic interest rate at 15%. The decision, which came on Wednesday, had been widely expected by analysts and marked the second consecutive time policymakers had kept rates unchanged. The move is consistent with the bank’s cautious approach to inflation as they pledged to maintain the rate, a key gauge of short-term health in the economy, at a very low level for an extended period.  They held out the possibility of ratcheting it up again should they sense inflationary pressures picking up. The statement underscored the bank’s desire to re-anchor overnight expectations and eventually bring inflation back to its 3% target.  The head of the Brazilian central bank, Gabriel Galípolo, emphasized vigilance, adding that monetary policy is the key and first line of defense against inflation, which nobody should expect him to ease quickly. Inflation shows mixed signals Recent data show inflation is beginning to cool, with consumer prices rising 5.13% in the 12 months through August, the second consecutive month of slower gains. Falling electricity and food costs helped ease household expenses, but services inflation remains stubbornly high. Economists warn that consecutive upticks in headline inflation could still unmoor long-term expectations. But inflation remains well above the target, and service prices are still increasing. Economists worry that such back-to-back gains could contribute to long-term inflation expectations. In its survey, Banco de México forecasts inflation will reach 4.83% in 2025 and slow to 4.30% by 2026. Both levels remain above the bank’s target rate of 3 percent, so it has been gun-shy thus far in cutting rates too aggressively. The Brazilian real, which has gained about 5% since the last meeting, also helps curb importing costs. However, worldwide conditions, from commodities to shifts in…
Share
BitcoinEthereumNews2025/09/18 08:38
Share